A PHASE 2, MULTI-COHORT, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF bb2121 IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND IN SUBJECTS WITH CLINICAL HIGH-RISK MULTIPLE MYELOMA (KarMMa-2)
Contact:
NCT Number:
Protocol:
AAAR9953
Study Status:
Active/Enrolling
Population:
Adult
Phase:
II
The purpose of this study is to determine if the investigational therapy called bb2121 is effective in treating multiple myeloma. bb2121 is a type of therapy known as chimeric antigen receptor (CAR) T cell therapy. T cells are a kind of white blood cell which form part of your body’s immune system. Your T cells will be separated from the rest of the immune cells and then modified to make the bb2121 T cells. The bb2121 T cells manufactured for you will be shipped to the study site when you are ready for the treatment and infused back into your blood.
Are you Eligible? (Inclusion Criteria)
- Are you 18 years of age or older?
- Were you diagnosed with multiple myeloma?
- Did your cancer return after your most recent treatment regimen, or has your
- cancer not responded to your most recent treatment regimen?
Specialty Area(s)
Multiple Myeloma/Amyloidosis, Cell Therapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
